Altamira Therapeutics Ltd. - Common Shares (NQ:CYTO)

0.3001 UNCHANGED

Last Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altamira Therapeutics Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Is Altamira Therapeutics (CYTO) Stock Up 70% Today? ↗

October 21, 2022

Altamira wants to be a leaner, more focused business, and a decision to divest certain assets has CYTO stock traders feeling bullish today.

Via InvestorPlace

Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets

October 21, 2022

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics to Participate at RNA Leaders USA Congress

October 13, 2022

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

October 03, 2022

From Altamira Therapeutics Ltd

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

September 16, 2022

We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them!

Via InvestorPlace

Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study ↗

May 20, 2022

Via Benzinga

Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday ↗

September 23, 2022

Gainers

Via Benzinga

Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session ↗

September 22, 2022

Gainers

Via Benzinga

Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal

July 28, 2022

•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint...

From Altamira Therapeutics Ltd

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

August 02, 2022

Tuesday's session saw 63 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 22, 2022

During Friday's session, 61 companies made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 25, 2022

On Monday, 100 companies reached new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 21, 2022

During Thursday's trading, 50 companies set new 52-week lows.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

July 20, 2022

Investors ready to start trading early this morning will want to check out the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

Dow Surges 500 Points; Johnson & Johnson Lowers Guidance ↗

July 19, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.

Via Benzinga

July 20, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...

Via Benzinga

This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session ↗

July 19, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue...

Via Benzinga

Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal

July 12, 2022

HAMILTON, BERMUDA / ACCESSWIRE / July 12, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical...

From Altamira Therapeutics Ltd.

Via AccessWire

Topics Death

Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan

June 29, 2022

Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses

From Altamira Therapeutics

Via AccessWire

Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis

June 27, 2022

HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...

From Altamira Therapeutics

Via AccessWire

Stocks That Hit 52-Week Lows On Tuesday ↗

June 28, 2022

On Tuesday, 87 companies hit new 52-week lows.

Via Benzinga

Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19

June 23, 2022

HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...

From Altamira Therapeutics

Via AccessWire

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗

June 28, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session ↗

June 27, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo

June 13, 2022

HAMILTON, BERMUDA / ACCESSWIRE / June 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...

From Altamira Therapeutics Ltd.

Via AccessWire

Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements

June 09, 2022

HAMILTON, BERMUDA / ACCESSWIRE / June 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...

From Altamira Therapeutics

Via AccessWire

Topics Intellectual Property Regulatory Compliance

Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray

June 08, 2022

HAMILTON, BERMUDA / ACCESSWIRE / June 8, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...

From Altamira Therapeutics

Via AccessWire

Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia

May 31, 2022

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that...

From Altamira Therapeutics

Via AccessWire

Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray

May 23, 2022

HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...

From Altamira Therapeutics

Via AccessWire

Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study

May 20, 2022

Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safety

From Altamira Therapeutics

Via AccessWire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.